All patients received Liposomal Amphotericin B, and nine (69.2%) patients received sequential posaconazole therapy. A total of eight (61.5%) patients, including three (23%) patients with intracranial involvement, died. Mucormycosis is a severe infection, especially in patients with hematological malignancies or DM, despite early diagnosis and combined antifungal and surgical treatments.

By utilising gene-edited HIOs derived from the same donor, we reveal epithelial cell-intrinsic mechanisms downstream of CFTR loss. These findings, enabled by our experimental approach, offer important insights into the role of the intestinal epithelium in CF, independent of immune cells, the microbiome, and inflammation. They also lend support for therapeutic targeting of calcium signalling to reverse disease-associated transcriptomic changes.

P4, N=100, Recruiting, Weill Medical College of Cornell University | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027

Azacitidine was administered after dialysis sessions, while venetoclax dosing was adjusted because of concomitant posaconazole prophylaxis. Approximately one year after diagnosis, relapsed AML was identified on peripheral blood flow cytometry. This case highlights the feasibility of venetoclax-based lower-intensity therapy in selected dialysis-dependent AML patients while underscoring the persistent therapeutic limitations and adverse prognosis associated with relapsed disease in this population.

Compound 3 (3α-dihydrocadambine) effectively revealed strong vasodilatory activity with EC50 values of 2.4 μM and 2.1 μM, respectively, similar levels comparable to the positive control (verapamil)...Moreover, network pharmacology and molecular docking predicted compound 1 to correlate with the p53-Hippo-TGF-β antitumor signalling pathway and compound 3 with the cAMP/cGMP-PKG cardiovascular signalling pathway. This work provides preliminary experimental data for the development of potential lead compounds from U. gambir.

P2, N=82, Completed, Post Graduate Institute of Medical Education and Research, Chandigarh | Recruiting --> Completed | N=50 --> 82 | Trial completion date: Jul 2025 --> Feb 2026 | Trial primary completion date: Dec 2024 --> Feb 2026

Midostaurin clearance was delayed during co-administration. Midostaurin therapeutic drug monitoring may serve for decision-making when DDI with CYP3A4 inhibitors is suspected.

P3, N=664, Not yet recruiting, University of Minnesota | Initiation date: May 2026 --> Sep 2026

Azacitidine/venetoclax is the standard treatment for patients with acute myeloid leukemia (AML) unfit for intensive chemotherapy. The potentiated antileukemic activity positions cobicistat as a promising complementary agent in AML therapy. This trial was registered at www.clinicaltrials.gov as NCT06014489.

Celastrol reduced P-gp expression and increased intracellular drug accumulation, comparable to verapamil. Celastrol synergizes with 5-FU to overcome chemoresistance in osteosarcoma by enhancing p53-mediated and -independent apoptosis and inhibiting P-gp-mediated drug efflux. These findings suggest a promising low-toxicity therapeutic strategy, warranting further in vivo and clinical investigations.

P=N/A, N=100, Not yet recruiting, Assiut University

This study describes, for the first time in literature, a suitable approach to develop co-encapsulated magnetic nanoparticles based on fluorescent biotinylated N-palmitoyl chitosan, hydrophobic magnetite, Docetaxel and Verapamil. No significant toxicity was observed for magnetic nanoparticles in the rats. Overall, these findings suggest that the developed magnetic nanoplatforms represents a promising candidate for breast cancer applications and merits further in vivo investigation needed to elucidate the action mechanism of encapsulated therapeutics and their pharmacologic activity.